Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
September 29, 2008
- Long-term Hospitalization for Schizophrenia Causes Problems in IADL
September 29, 2008
- DTP Focused on at 2008 IFPW General Membership Meeting
September 29, 2008
- Many Physicians Lack Accurate Knowledge about Medicinal Narcotics
September 29, 2008
- Chugai Relaxes Post-Marketing Safety Measures for Avastin
September 22, 2008
- R&D NEWS IN BRIEF
September 22, 2008
- More PE Specialists Needed to Enhance PM Safety Measures: Mr Kokan
September 22, 2008
- SEMINAR／New Drugs for Diabetic Nephropathy Needed: JHSF Seminar
September 22, 2008
- GENERICS NEWS IN BRIEF
September 22, 2008
- NovoRapid 30 Mix Decreases HbA1c without Increasing Incidence of Serious Hypoglycemic Events
September 22, 2008
- BUSINESS NEWS IN BRIEF
September 22, 2008
- Saxagliptin Effective in Combination with Other Oral Antidiabetic Agents
September 22, 2008
- Japanese Pharma Industry Group Visits UCB
September 22, 2008
- RAD001 Granted Priority Review Status in the US
September 22, 2008
- Meiji Seika, Meiji Dairy to Integrate Businesses
September 22, 2008
- Will Distribution Practices Be Improved? Part 2
September 22, 2008
- NovoRapid 30 Mix Has Turned Out to Be Global Blockbuster: Novo Nordisk Pharma
September 22, 2008
- Kissei Licenses Monoclonal Antibody from Y's Therapeutics
September 22, 2008
- Global Market for Monoclonal Antibodies to Expand to $49 Bil. in 2013: Datamonitor
September 22, 2008
- Eli Lilly Japan Aims at $1 Bil. in 2010, $2Bil. in 2015: Mr Zulueta
September 22, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…